Revelation Biosciences, Inc. (REVB) stock

REVBNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVBW

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30

$4.26−0.12 (-2.63%)

Close on Nov 13, 2026Market cap $2.91MP/E –Yield –

Revelation Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Revelation Biosciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?